Zogenix, Inc (ZGNX) has announced that the U.S.
Zogenix, Inc. (NASDAQ:ZGNX) announced new data demonstrating effectiveness and cardiovascular-related safety for patients treated with ZX008 (low-dose fenfluramine) as an adjunctive therapy for …
Zogenix, Inc. (NASDAQ:ZGNX) provided a corporate update and announced financial results for the third quarter ended September 30, 2016.
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the Company …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, announced that it has entered into an …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, announced new data which continues to …
Healthcare analysts came out today with research notes on a handful of biotechnology and medical stocks. Among the equities in focus are cancer …
